Suppr超能文献

硝酸镓用于晚期骨佩吉特病:有效性及剂量反应分析。

Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis.

作者信息

Warrell R P, Bosco B, Weinerman S, Levine B, Lane J, Bockman R S

机构信息

Hospital for Special Surgery, New York, New York.

出版信息

Ann Intern Med. 1990 Dec 1;113(11):847-51. doi: 10.7326/0003-4819-113-11-847.

Abstract

OBJECTIVE

To evaluate whether a brief course of treatment with gallium nitrate can reduce biochemical parameters of accelerated bone turnover in patients with advanced Paget disease.

DESIGN

Unblinded trial, decreasing dose schedules of gallium nitrate.

SETTING

University hospital with primary orthopedic and metabolic bone disease specialty.

PATIENTS

Ten patients with advanced Paget disease who had previously received conventional therapy consisting of calcitonin, etidronate, or mithramycin.

INTERVENTIONS

Five patients were entered into each of three dose schedules: 2.5 mg/kg body weight per day by continuous intravenous infusion for 7 days; 0.5 mg/kg per day for 14 days by subcutaneous injection; and 0.25 mg/kg per day for 14 days by subcutaneous injection. Several patients were treated with different dose schedules. Patients were followed until relapse.

RESULTS

Fifteen courses of treatment were administered to ten patients. Reductions in serum alkaline phosphatase and urinary hydroxyproline excretion were observed after treatment with each dose schedule. After treatment with high, intermediate, and low doses, the median maximum decreases in serum alkaline phosphatase activity were 49%, 39%, and 18%, respectively. The median maximum decreases in urinary hydroxyproline excretion were 50%, 52%, and 16%, respectively. The maximum decrease in urinary hydroxyproline excretion occurred within a median of 2 weeks from the start of treatment, whereas the maximum decrease in serum alkaline phosphatase activity occurred substantially later at a median of 6 weeks. All treatment schedules were well tolerated. Response duration was highly variable (range, 6 to 42 weeks).

CONCLUSIONS

Short-term treatment with gallium nitrate can reduce biochemical parameters of disease activity in patients with advanced Paget disease of bone. Larger trials using low-dose intermittent treatment schedules are required to evaluate the safety and effectiveness of this therapy.

摘要

目的

评估硝酸镓短期疗程治疗能否降低晚期佩吉特病患者骨转换加速的生化指标。

设计

非盲试验,硝酸镓剂量递减方案。

地点

设有骨科和代谢性骨病专科的大学医院。

患者

10例晚期佩吉特病患者,此前接受过降钙素、依替膦酸或光辉霉素的常规治疗。

干预措施

10例患者分入3种剂量方案组,每组5例:连续静脉输注,每日2.5mg/kg体重,共7天;皮下注射,每日0.5mg/kg,共14天;皮下注射,每日0.25mg/kg,共14天。部分患者接受了不同剂量方案的治疗。随访患者直至复发。

结果

10例患者共接受了15个疗程的治疗。各剂量方案治疗后,血清碱性磷酸酶及尿羟脯氨酸排泄均下降。高、中、低剂量治疗后,血清碱性磷酸酶活性最大降幅中位数分别为49%、39%和18%。尿羟脯氨酸排泄最大降幅中位数分别为50%、52%和16%。尿羟脯氨酸排泄最大降幅出现在治疗开始后中位数2周内,而血清碱性磷酸酶活性最大降幅出现得晚得多,中位数为6周。所有治疗方案耐受性良好。缓解持续时间差异很大(范围6至42周)。

结论

硝酸镓短期治疗可降低晚期骨佩吉特病患者疾病活动的生化指标。需要开展更大规模的试验,采用低剂量间歇治疗方案来评估该疗法的安全性和有效性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验